Kyoto University Hospital

STOCKHOLM, June 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce a milestone in radiotherapy technology where RaySearch's RayStation®* was used for the world's first clinical treatment using OXRAY, a new treatment machine from Hitachi. The event took place on June 17 at Narita Memorial Hospital in Toyohashi, Japan. OXRAY represents a pioneering radiotherapy system featuring a Gimbal-mounted beam delivery system. RayStation was used to drive its motion tracking functionality, dual-source CBCT image-guided radiotherapy for precise patient positioning, and dynamic swing arc capabilities. Developed in collaboration with Kyoto University Hospital, the OXRAY system has been seamlessly integrated into RayStation through close collaboration between RaySearch and Hitachi. By joining the innovative capabilities of OXRAY with RayStation's sophisticated planning software, clinicians can achieve unprecedented precision and flexibility in radiation therapy, ensuring optimal patient outcomes. Dr. Yuta Shibamoto, MD of the Meiyo-kai Narita Memorial Hospital group says: "There are so many different cases and challenges we face in daily practice. Having the latest technique will enhance the possibilities of our treatment. We are looking forward to the solution that OXRAY and RayStation brings in." Johan Löf, Founder and CEO of RaySearch, remarked, "The OXRAY system represents a remarkable convergence of advanced radiotherapy technologies. By combining non-coplanar treatments, superior imaging capabilities, a conventional MLC, and real-time tracking, OXRAY delivers a new level of precision and flexibility. The integration with RayStation underscores our commitment to pioneering solutions that enhance cancer treatments." About Narita Memorial Hospital Narita Memorial Hospital, located in Toyohashi City, is part of the Meiyo-kai Hospital group, a distinguished healthcare provider founded in 1951. In 2012, Narita Memorial Hospital established itself as an early adopter of advanced radiotherapy techniques by introducing TomoTherapy. Narita Memorial Hospital achieved another milestone in 2018 by becoming the first healthcare facility in Japan to implement the IBA Proteus One system. About RaySearch RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to more than 1,000 centers in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com. About RayStation RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved. * Subject to regulatory clearance in some markets. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected] This information was brought to you by Cision The following files are available for download: SOURCE RaySearch Laboratories

Recent achievements showcase company’s leadership as CRO Partner and Employer of Choice in the Asia/Pacific regionBOSTON and DURHAM, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced recent achievements demonstrating its strength in the Asia/Pacific region as a CRO partner for customers and Employer of Choice for colleagues committed to making a difference for patients. Notable recognitions include earning the 2022 India Workplace Equality Index (IWEI)’s Top Employers Award for the third consecutive year, receiving the 2022-2023 Mercer China Healthiest Workplace Awards for Outstanding Health Practice Award for providing flexible work arrangements to colleagues and marking the company’s 25th anniversary in Japan as one of the longest tenured global CROs in the country. “Asia/Pacific is a strategically important region of growth and investment for our local and global biotech and pharma customers and for Parexel,” said Peyton Howell, Chief Commercial and Growth Officer. “We’re honored to be recognized consistently for our culture of inclusion and workplace flexibility, and are proud to celebrate 25 years in Japan, a testament to our commitment to and extensive experience in the region.” Recognized with the 2022 IWEI Top Employer Award in the Bronze category, Parexel was selected for developing inclusive policies and initiating activities that promote LGBT+ inclusion for colleagues. Parexel has received the IWEI Top Employer Award each year since 2020. The IWEI is India’s only comprehensive benchmarking tool for companies to measure their progress on LGBT+ inclusion. Parexel also received the Outstanding Health Practice Award at the 2022-2023 Mercer China Healthiest Workplace Awards in Shanghai for its flexible work program. By better understanding the specific needs of its colleagues and enabling them to choose the work environment that supports their professional and personal development, Parexel has effectively improved employee engagement and cultivated a greater sense of belonging across its employee base. Launched in 2016 by a leading professional consulting firm in employee health and benefits, the Mercer China Healthiest Workplace Awards spotlight employers in China who provide the healthiest working environments for the sake of improving overall employee health and wellbeing. As one of the largest and longest-tenured global CROs in Japan, Parexel recently celebrated more than two decades of operations in the country. Parexel Japan has more than 1,000 colleagues across three strategic locations – Kobe, Tokyo and Osaka. With a focus on Patients-First and site relationships, Parexel Japan has conducted nearly 500 clinical trials that have served 170,000 patients, collaborated with over 40,000 site investigators and formed strategic alliances with Kyoto University Hospital, Osaka International Cancer Institute (OICI) and ASird’s STEP (Strategic Translational Action for Empowering Patients) program. About ParexelParexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com and follow us on LinkedIn, Twitter, Facebook and Instagram. MEDIA Lori Preuit Dorer+1 513 496 8121Lori.Dorer@parexel.com Danaka Williams+1 984 298 4207Danaka.Williams@parexel.com

Bedford, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Cell sorting technology leader and innovator Cytonome-ST, LLC, has assisted Japanese pharmaceutical firm Sumitomo Dainippon Pharma Co., Ltd. to produce enough human stem cells to proceed with a clinical trial of a new treatment aimed at curing Parkinson’s Disease. Cytonome-ST  is a biotechnology instrument design company and subsidiary of biotechnology, bioelectronics, and bioinformatics leader and innovator STgenetics. Cytonome has developed the most advanced parallel microfluidic cell sorting and cell handling technologies in the world and produces the GigaSort® GMP cell sorting platform, the only parallel microfluidic cell sorter capable of effectively processing the large volumes required of cellular therapeutics in a gentle and efficient manner. Sumitomo Dainippon Pharma Co., Ltd. has reached an important milestone to provide manufactured iPS cell derived dopaminergic progenitor cells to Kyoto University Hospital for an investigator-initiated clinical study by Kyoto University and CiRA to evaluate the safety and efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease (). This cellular therapy involves a special type of human cells which can become stem cells. Stem cells can change into different cell types including neurons or brain cells. Sumitomo Dainippon Pharma increases the quantity of neurons through cell culture expansion. Not all cells produced through this method are suitable for therapeutic treatment, so they must be separated from suitable cells using the GigaSort® platform. After separation, suitable cells are implanted into the brain of a Parkinson’s patient, which is known as cell replacement therapy. Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma, comments, “This technique is very unique and plays one of the important roles in our manufacturing activities.” John Sharpe, Cytonome-ST Chief Operating Officer, said, “We are very excited to be able to support Sumitomo Dainippon Pharma’s manufacturing process. We believe that this ground-breaking trial, if successful, has the potential to help many patients and families around the world that are effected by Parkinson’s disease, and we feel privileged to play a part in collaboration with Sumitomo Dainippon Pharma.” About Cytonome-ST, LLC Based in Bedford, MA, Cytonome-ST develops advanced solutions in cell purification and cell handling for the bioprocessing, industrial, and life science research markets. With deep engineering expertise in the cytometry field and a strong intellectual property portfolio, Cytonome-ST aims to develop products that simplify existing cell handling workflows and that enable transformational cell-based outcomes. Based in Navasota, Texas, STgenetics uses transformational technology to create products and services for animal protein producers to achieve sustainability and production goals. Check with local and national authorities for any license, approval, or clearance requirements in using GigaSort® technologies for the development of commercial therapies. In the USA, the GigaSort® system is for Research Use Only. Not for use in diagnostic or therapeutic procedures without appropriate FDA approvals. For more information on Cytonome-ST and the GigaSort® GMP cell sorting platform, please visit . For more information on STgenetics, go to . -30-